为何证据生成对支付方至关重要以及支付方如何助力
文章指出美国虽在新产品上市领先,但上市后证据生成能力不足,私人支付方的作用被低估。支付方通过参与减少临床试验行政财务障碍、资助高优先级试验、加强与产业界沟通证据需求、改善理赔数据可用性等步骤,可促进证据生成,使临床研究和监测系统反映全美临床现实,惠及创新生态所有参与者。
要点
- 支付方是改善证据生成的关键盟友,其政策影响诊疗与研究,理赔数据可作真实世界证据来源。
- 支付方可采取多种步骤改善证据生成,如资助潜在节省成本的试验、减少数据滞后、记录器械唯一标识符。
- 支付方广泛参与FDA证据生成建议,可确保临床研究机会覆盖所有社区,证据反映全美临床现实。
核心结论
- 增加支付方对证据生成的参与可使医疗创新生态系统的所有参与者受益,其重要性将因护理与研究整合、社区参与和替代支付模式而持续增长。
研究设计与样本
- 本文为观点类文章,基于对美国上市后证据生成现状的观察,提出支付方可采取的若干关键步骤,未涉及系统检索或原始研究样本。
主要发现
- 支付方是改善证据生成的关键盟友,因为更好的数据可改善覆盖决策,其政策影响诊疗与研究行为,理赔数据是医疗产品评价的真实世界证据来源。
- 支付方有动力改善证据生成,因为产品上市时通常缺乏 informing 医疗与覆盖决策所需的证据,若无支付方参与此类证据可能不会产生。
- 支付方可采取的关键步骤包括参与减少临床试验行政与财务障碍、资助潜在节省成本的试验以激励高优先级问题证据生成、加强与医疗产品行业就覆盖决策证据需求沟通、通过减少数据滞后和常规记录唯一器械标识符改善理赔数据可用性。
临床怎么用
- 原文未据此给出推荐。文章提出支付方可采取的关键步骤包括参与减少临床试验障碍、资助高优先级试验、加强与产业界沟通、改善理赔数据可用性。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The US leads the world in bringing new medical products to market, but the ability to generate evidence to inform clinical practice in postmarket settings needs improvement. Although a diverse group of stakeholders is working to improve postmarket evidence generation, the role of private payers has been underappreciated. OBSERVATIONS: Payers are crucial allies in improving evidence generation because better data would better inform coverage decisions, their policies and practices influence the conduct of care and research, and their claims data are a source of real-world evidence used in medical product evaluation. In addition, payers have a stake in improving evidence generation because the kinds of evidence needed to inform health care and coverage decisions are often not available when a product enters the market and may not be generated without their involvement. Here, we describe several key steps payers could take to improve evidence generation, including participating in efforts to reduce administrative and financial barriers to the conduct of clinical trials, directly incentivizing evidence generation on high-priority questions by funding potential cost-saving trials, increasing engagement with the medical products industry on evidentiary needs for coverage decisions, and improving usability of claims data by reducing data lags and routinely recording unique device identifiers. Broad payer engagement with US Food and Drug Administration recommendations regarding evidence generation will ensure that the opportunities to participate in clinical research are extended to all communities and that evidence needed to inform care is generated in trials and surveillance systems that reflect the clinical reality across the US. CONCLUSIONS AND RELEVANCE: Increasing payer involvement in evidence generation can benefit all participants in the medical innovation ecosystem. The importance of payers in these efforts will continue to grow in response to imperatives to increase integration of care and research, engage a diverse set of communities in clinical research, and move toward alternative payment models.
引用
- Abbasi AB, Curtis LH, Fleisher LA, et al. Why Evidence Generation Should Matter to Payers and How They Can Help. JAMA. 2024. PMID: 38949829. doi:10.1001/jama.2024.7616
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。